GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OTCPK:AKBLF) » Definitions » Earnings Yield (Joel Greenblatt) %

AKBLF (Alk-Abello AS) Earnings Yield (Joel Greenblatt) % : 4.11% (As of Mar. 2025)


View and export this data going back to 2009. Start your Free Trial

What is Alk-Abello AS Earnings Yield (Joel Greenblatt) %?

Alk-Abello AS's Enterprise Value for the quarter that ended in Mar. 2025 was $4,446.9 Mil. Alk-Abello AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $184.7 Mil. Alk-Abello AS's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2025 was 4.11%.

The historical rank and industry rank for Alk-Abello AS's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

AKBLF' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2.09   Med: 1.39   Max: 8.09
Current: 3.31

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Alk-Abello AS was 8.09%. The lowest was -2.09%. And the median was 1.39%.

AKBLF's Earnings Yield (Joel Greenblatt) % is ranked better than
87.35% of 1312 companies
in the Biotechnology industry
Industry Median: -13.255 vs AKBLF: 3.31

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Alk-Abello AS's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2025 was 20.54%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Alk-Abello AS Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Alk-Abello AS's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Earnings Yield (Joel Greenblatt) % Chart

Alk-Abello AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.79 2.17 2.95 3.13

Alk-Abello AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.73 2.72 2.85 3.13 4.11

Competitive Comparison of Alk-Abello AS's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Alk-Abello AS's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Earnings Yield (Joel Greenblatt) % falls into.


;
;

Alk-Abello AS Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Alk-Abello ASs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2024 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=157.538/5032.254
=3.13 %

Alk-Abello AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $184.7 Mil.



Alk-Abello AS  (OTCPK:AKBLF) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Alk-Abello AS Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Industry
Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

From GuruFocus

Q3 2024 ALK-Abello A/S Earnings Call Transcript

By GuruFocus News 11-18-2024

ALK-Abello A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-12-2024

Q1 2023 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2020 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q4 2019 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2020 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2021 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2024 ALK-Abello A/S Earnings Call Transcript

By GuruFocus News 10-09-2024

Q3 2021 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024